In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Aimmune Therapeutics (AIMT), with a price target of $79. The company’s shares closed last Monday at $20.54.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -14.3% and a 27.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.
Aimmune Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $49, representing a 136.4% upside. In a report issued on August 8, RBC Capital also maintained a Buy rating on the stock with a $50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.12 and a one-year low of $16.95. Currently, Aimmune Therapeutics has an average volume of 541.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
